<DOC>
	<DOCNO>NCT00759161</DOCNO>
	<brief_summary>The purpose study determine safety efficacy AN2728 Ointment , 5 % , compare Ointment Vehicle treatment plaque type psoriasis .</brief_summary>
	<brief_title>Safety Efficacy Study A Novel Ointment Treat Plaque Type Psoriasis</brief_title>
	<detailed_description>This multi-center , randomize , double-blind bilateral design . Patients apply test article , AN2728 Ointment , 5 % , Ointment Vehicle twice daily . The assigned study medication apply two comparable treatment target plaque identify baseline . One test article apply one plaque test article anatomically distinct plaque . All efficacy evaluation measure two plaque identify baseline visit .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Male female &gt; 18 year age time enrollment . 2 . The clinical diagnosis stable plaque psoriasis . 3 . Two target plaque similar severity 1 . ≥ 5 cm2 ≤ 100 cm2 compute multiply great diameter plaque diameter plaque perpendicular great diameter . 2 . Bilaterally locate ( right/left ) plaques arm plaque locate upper low trunk . Plaques locate trunk separate least 10 cm designate Investigator either left/right front/back . 3 . Target plaque severity score 24 ( mild moderate ) . 4 . Normal clinically significant screen laboratory result . 5 . Subjects willing able apply study drug direct , comply study instruction , commit followup visit . 6 . Subjects ability understand , agree sign study Informed Consent Form ( ICF ) prior initiation protocol related procedure . 1 . Any dermatological condition could interfere clinical evaluation disease state physical condition might expose patient unacceptable risk study participation 2 . Any underlying disease ( ) dermatological condition require use exclusionary topical systemic therapy ( see ) 3 . Known sensitivity component study medication 4 . Spontaneously improve rapidly deteriorate psoriatic plaque pustular/exfoliative , guttate , erythrodermic nonplaque form psoriasis 5 . Concomitant use topical systemic therapy might alter course psoriasis 6 . Females child bear potential . Females must postmenopausal ( base FSH level ) surgically sterile ( oophorectomy ) 7 . Washout period : 1 . Topical drug might alter course psoriasis : 2 week 2 . Oral retinoids : 8 week 3 . Nonretinoid systemic drug might alter course psoriasis : 4 week 4 . PUVA : 4 week 5 . UVB therapy : 4 week 6 . Use emollients/moisturizers area ( ) treat : 2 day prior baseline visit 8 . AIDS AIDS relate illness 9 . Concurrent participation another drug research study within 30 day enrollment 10 . Use lithium hydroxychloroquine containing product ( i.e . Plaquenil ) 11 . Use betablocking medication ( i.e . propranolol ) dose stabilize least 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Plaque Type Psoriasis</keyword>
	<keyword>Topical</keyword>
</DOC>